How are you choosing between ipilimumab/nivolumab versus platinum/pemetrexed for unresectable epithelioid mesotheliomas?

Although the combination of ipi/nivo has been approved for all unresectable mesotheliomas, the benefit was much more impressive in the NON-epithelioid histologies. Therefore, for patients with epithelioid mesothelioma, I follow the NCCN recommendations where I would discuss both platinum/pemetrexed ...

The CheckMate 743 study [Baas et al., PMID 33485464] is an important trial for malignant mesothelioma that randomized 605 patients to first line ipilimumab + nivolumab versus platinum-pemetrexed chemotherapy. Based on a pre-specified interim analysis, ipilimumab + nivolumab extended overall survival...